128 related articles for article (PubMed ID: 25797571)
1. An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer.
Lee JY; Youm J; Kim JW; Kim K; Kim HJ; Cho JY; Kim MA; Park NH; Song YS
Cancer Res Treat; 2016 Jan; 48(1):259-65. PubMed ID: 25797571
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and U.S. perspectives.
Lee JY; Kwon JS; Cohn DE; Kim Y; Smith B; Lee TJ; Kim JW
Gynecol Oncol; 2016 Jan; 140(1):83-9. PubMed ID: 26548733
[TBL] [Abstract][Full Text] [Related]
3. MRI and PET/CT for triaging stage IB clinically operable cervical cancer to appropriate therapy: decision analysis to assess patient outcomes.
Pandharipande PV; Choy G; del Carmen MG; Gazelle GS; Russell AH; Lee SI
AJR Am J Roentgenol; 2009 Mar; 192(3):802-14. PubMed ID: 19234280
[TBL] [Abstract][Full Text] [Related]
4. Preoperatively Assessable Clinical and Pathological Risk Factors for Parametrial Involvement in Surgically Treated FIGO Stage IB-IIA Cervical Cancer.
Canaz E; Ozyurek ES; Erdem B; Aldikactioglu Talmac M; Yildiz Ozaydin I; Akbayir O; Numanoglu C; Ulker V
Int J Gynecol Cancer; 2017 Oct; 27(8):1722-1728. PubMed ID: 28617687
[TBL] [Abstract][Full Text] [Related]
5. Preoperative MRI criteria for trials on less radical surgery in Stage IB1 cervical cancer.
Lee JY; Youm J; Kim TH; Cho JY; Kim MA; Suh DH; Lim MC; Kim JW; Park NH; Song YS
Gynecol Oncol; 2014 Jul; 134(1):47-51. PubMed ID: 24768849
[TBL] [Abstract][Full Text] [Related]
6. Parametrial Involvement on Magnetic Resonance Imaging Has No Effect on the Survival of Early-Stage Cervical Cancer Patients.
Yang K; Park W; Huh SJ; Park BK; Kim CK; Kim BG; Bae DS; Lee JW
Int J Gynecol Cancer; 2017 Mar; 27(3):507-513. PubMed ID: 28129242
[TBL] [Abstract][Full Text] [Related]
7. Value of PET-CT in avoiding multimodality therapy in operable cervical cancer.
Goyal BK; Singh H; Kapur K; Duggal BS; Jacob MJ
Int J Gynecol Cancer; 2010 Aug; 20(6):1041-5. PubMed ID: 20683414
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study.
Kong TW; Lee JD; Son JH; Paek J; Chun M; Chang SJ; Ryu HS
Gynecol Oncol; 2016 Oct; 143(1):77-82. PubMed ID: 27423377
[TBL] [Abstract][Full Text] [Related]
9. Validity of laparoscopic staging to avoid adjuvant chemoradiation following radical surgery in patients with early cervical cancer.
Marnitz S; Köhler C; Affonso RJ; Schneider A; Chiantera V; Tsounoda A; Vercellino F
Oncology; 2012; 83(6):346-53. PubMed ID: 23006972
[TBL] [Abstract][Full Text] [Related]
10. The role of magnetic resonance imaging in pretreatment evaluation of early-stage cervical cancer.
Zhang W; Zhang J; Yang J; Xue H; Cao D; Huang H; Wu M; Cui Q; Chen J; Lang J; Shen K
Int J Gynecol Cancer; 2014 Sep; 24(7):1292-8. PubMed ID: 24987919
[TBL] [Abstract][Full Text] [Related]
11. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
[TBL] [Abstract][Full Text] [Related]
12. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.
Monk BJ; Cha DS; Walker JL; Burger RA; Ramsinghani NS; Manetta A; DiSaia PJ; Berman ML
Gynecol Oncol; 1994 Jul; 54(1):4-9. PubMed ID: 8020837
[TBL] [Abstract][Full Text] [Related]
13. Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Zheng M; Huang L; Liu JH; Xiong Y; Li JD; Huang X; He L; Ren YF; Wang HY
J Surg Oncol; 2011 Oct; 104(5):480-5. PubMed ID: 21538358
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of maximally aggressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients.
Elliott KS; Borowsky ME; Malka ES; Scudder SA; Leiserowitz GS; Russell AH
J Reprod Med; 2006 May; 51(5):383-8. PubMed ID: 16779984
[TBL] [Abstract][Full Text] [Related]
15. Preoperative nomogram for prediction of microscopic parametrial infiltration in patients with FIGO stage IB cervical cancer treated with radical hysterectomy.
Kong TW; Kim J; Son JH; Kang SW; Paek J; Chun M; Chang SJ; Ryu HS
Gynecol Oncol; 2016 Jul; 142(1):109-114. PubMed ID: 27179979
[TBL] [Abstract][Full Text] [Related]
16. A Predictive Model for Parametrial Invasion in Patients With FIGO Stage IB Cervical Cancer: Individualized Approach for Primary Treatment.
Kong TW; Piao X; Chang SJ; Paek J; Lee Y; Lee EJ; Ryu HS
Int J Gynecol Cancer; 2016 Jan; 26(1):184-91. PubMed ID: 26512782
[TBL] [Abstract][Full Text] [Related]
17. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.
Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH
Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284
[TBL] [Abstract][Full Text] [Related]
18. Parametrial involvement in FIGO stage IB1 cervical carcinoma diagnostic impact of tumor diameter in preoperative magnetic resonance imaging.
Kamimori T; Sakamoto K; Fujiwara K; Umayahara K; Sugiyama Y; Utsugi K; Takeshima N; Tanaka H; Gomi N; Takizawa K
Int J Gynecol Cancer; 2011 Feb; 21(2):349-54. PubMed ID: 21721193
[TBL] [Abstract][Full Text] [Related]
19. Survival and prognostic factors comparing stage IB 1 versus stage IB 2 cervical cancer treated with primary radical hysterectomy.
Srisomboon J; Kietpeerakool C; Suprasert P; Manopanya M; Siriaree S; Charoenkwan K; Cheewakriangkrai C; Sae-Teng C
Asian Pac J Cancer Prev; 2011; 12(7):1753-6. PubMed ID: 22126559
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.
Ayhan A; Al RA; Baykal C; Demirtas E; Ayhan A; Yüce K
Int J Gynecol Cancer; 2004; 14(2):286-92. PubMed ID: 15086728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
